revenu primarili grant revenu
includ grant revenu estim due
limit visibl time
rsv nanoflu vaccin offer one-two
punch initi outperform pt
initi coverag outperform rate pt stanc base balanc
pipelin two late-stag readout expect optim phase rsv
vaccin studi demonstr infect expect
rsv program gener peak sale due first-to-market posit
potenti upsid off-label use elderli view nanoflu vaccin
program underappreci upsid base potenti better potenc
market share leader fluzon hd nanoflu confirm superior hai titer
strain influenza phase ii develop expect program move rapidli
phase studi posit data program
rsv common caus hospit us children
age nanoparticl rsv program posit first vaccin
prevent infect high-risk newborn popul given unmet need
believ efficaci may suffic support fda approv
reduct would creat formid clinic barrier entri
believ failur rsv nanoparticl vaccin phase studi sept
overhang share least partial unwarr
program differ product construct adjuv newborn studi vs
unadjuv elderli immunolog profil immun nave vs immun
patient phase studi vaccin demonstr reduct
infect day follow-up analysi repres expect
enrol give us confid potenti success
result phase elderli program confound low infect rate
singl rsv season phase newborn program conduct year
increas probabl infect rate closer expect level
maintain statist power
expect phase ii nanoflu data confirm potenti best-in-class potenc flu
vaccin flu program focu mani investor believ data
recapitul phase iia result increas hai titer vs activ control
strain offer downsid support valuat
year price histori
develop nanoparticle-
prevent viral
infect includ rsv influenza
analyst certif import disclosur see disclosur
rsv vaccin demonstr reduct seriou rsv
infect phase studi matern vaccin protect
phase ii nanoflu studi demonstr hai titer strain
compar better fluzone-hd
off-label commerci use rsv vaccin approv
elderli adult
nanoflu complet phase develop flu season
posit data either phase rsv vaccin studi
newborn phase ii flu vaccin studi
support meaning busi develop includ
potenti sale compani view posit rsv inform
analysi suggest efficaci demonstr efficaci
palivizumab-lik antibodi protect newborn
support posit phase outcom robust result
prior fail phase studi elderli popul
flu hai titer par better fluzone-hd could
disrupt market lead new standard care elderli
top-lin data phase rsv studi matern vaccin
top-lin data phase ii dose-find studi quadrival
protect newborn
busi develop rsv flu program includ
potenti sale compani
bla submiss rsv nanoparticl vaccin matern
vaccin protect newborn
success expans rsv vaccin usag copd elderli
govern ngo support expans nanoflu global
manufactur suppli chain secur favor access
model revenu north america busi
develop may acceler access rsv nanoflu
vaccin outsid north america
rsv vaccin demonstr less efficaci estim lower
bound fda submiss
acip declin provid posit recommend rsv vaccin
due limit clinic signific phase result
unexpect safeti signal either rsv flu program
nanoflu hai tier superior exist quadrival vaccin
would support continu develop
price target base dcf analysi assum discount rate million share fulli dilut basi estim termin
year estim long term revenu growth rate
risk clinic trial failur phase rsv program failur nanoflu demonstr differenti efficaci profil
commerci avail flu vaccin disrupt manufactur suppli chain includ scale-up rsv nanoflu program
commerci scale reimburs first-in-class potenti best-in-class vaccin offer premium price
note see stock trade specul appropri risk toler investor
initi coverag buy pt
initi coverag outperform rate price
target would look accumul share prior two import clinic updat
phase matern vaccin data rsv program phase ii
proof-of-concept data quadrival influenza vaccin offer potenti better
potenc compet vaccin view product offer potenti becom
standard care soc base first-in-class rsv best-in-class product profil
potenc influenza elderli peak sale estim rsv program
exclud off-label use elderli influenza vaccin
term near-term new flow expect result influenza data releas earli
januari rsv phase data late price target base
dcf analysi assum discount rate million share fulli dilut basi
termin year long-term growth rate
signific unmet need rsv vaccin
center diseas control cdc estim rsv infect account
hospit death year unit state mortal
concentr infant elderli infect rate compar
industri countri despit signific public health need strategi prevent
infect develop vaccin stymi histori enhanc
respiratori diseas formalin-inactiv alum-precipit rsv fi-rsv vaccin
develop subunit vaccin demonstr limit potenc
prematur newborn far less live birth receiv monthli inject
monoclon antibodi synagi prevent rsv infect first year despit
limit popul sale synagi peak given
signific econom burden infect newborn view price per
dose may warrant result address market exceed develop
rsv vaccin build demonstr efficaci synagi newborn
nvax rsv vaccin develop strategi base recombin nanoparticl
respiratori syncyti viru rsv protein type ii bind site
rsv bind site target synagi monoclon antibodi addit
rsv conserv across nearli strain rsv potenti support
develop univers vaccin littl issu season drift
target rsv new uniqu compani insect cell
platform may result protein fold close mimic natur configur
vaccin incorpor full length protein cleav disulfide-
link trimer form micel theori close
match natural-configur protein result robust
immunogen also antibodi potent natur occur rsv
believ failur septemb differ formul rsv
nanoparticl vaccin phase studi elderli patient understand concern
investor howev believ extrapol experi elderli
popul warrant due differ product construct adjuv newborn
studi vs unadjuv elderli immunolog profil immun nave vs immun
experienc understand biolog rsv infect monoclon antibodi
type ii bind site proven effect newborn vs limit data elderli popul
importantli actual data support clinic efficaci newborn none
studi rsv vaccin demonstr clinic efficaci adult
popul specif interim inform analysi conduct decemb
patient phase program demonstr reduct infect
day follow-up analysi repres expect phase enrol
give us confid potenti success
rsv revenu
us matern vaccin market adopt curv assum launch
total number birth expect increas us histor rate
annual result increas number live birth million
assum roughli expect mother million attend major
prenat visit ob/gyn theoret maximum market size base data
acog survey assum women receiv appropri prenat care
receiv season influenza vaccin pregnanc target market million
birth annual expect nvax vaccin achiev peak market share
target market roughli million dose price around
sale us global forecast peak sale
exclud use elderli high-risk adult popul
copd
nanoflu data suggest better potenc fluzon hd
paper publish vaccin evalu nanoflu commerci avail
trival fluzon hd fluzon quadrival ferret model total cohort
serolog neg subject inocul inject week apart day
week dose subject challeng one differ strain viru
nasal wash collect everi day day hai titer collect day
fold higher higher strain compar fluzon
hd hai titer victoria strain higher microneutr titer gener
correl hai titer nasal wash viral titer lower nanoflu subject
time point reach lower limit quantif day compar day
fluzon hd viral titer data combin hai find suggest potenti
superior protect nanoflu particularli elderli popul fluzon
hd current standard care high-risk popul
nanoflu sale driven elderli patient
forecast call compani win fda approv season influenza vaccin
assum price line product per dose price
increas time expect captur us market
million dose translat peak us sale
global peak sale figur
initi biotim outperform molecular templat
price target share base discount cash flow dcf
model sale rsv vaccin matern vaccin nanoflu prevent
influenza infect includ potenti revenu use rsv
vaccin elderli copd patient could offer signific upsid
model call compani commerci asset unit state
field sale forc repres focus primarili pediatr rsv
market expect seek commerci partner outsid us
receiv econom equival net royalti expect compani
achiev profit begin pay tax effect tax rate
forecast call total revenu last year dcf model
roughli gross revenu us sale remaind intern
market final year dcf valuat forecast free cash flow
driven sale nanoflu total revenu dcf model assum
discount rate long-term revenu growth rate share count million
oppenheim co inc estim compani document
view discount rate basi point higher typic
discount rate compani phase develop appropri given clinic
risk associ rsv vaccin develop balanc sheet roughli one
year cash long-term revenu growth rate bp standard
long-term growth rate biotechnolog compani believ growth rate estim
appropri given high barrier entri vaccin product potenti scale
nvax discoveri platform indic share count million assum
cash convers roughli million option convers outstand convert
note model call current cash balanc fund oper
increment capit requir roughli achiev profit
discount revenu dilut share million incom work free cash growth cash inc
next month expect top-lin phase data rsv program
matern vaccin phase ii nanoflu data import catalyst view
rsv data import potenti catalyst share base potenti
first approv product prevent rsv infect becom de facto
standard care term sequenc news flow nanoflu data like
releas januari rsv data late
optimist rsv studi meet reduct infect rate thresholdour
assumpt reduct minimum statist signific furthermor
believ result demonstr greater reduct could support discuss
fda given absenc exist vaccin high incid rsv infect among
newborn approach age year signific healthcar burdenrsv
infect among common caus hospit newborn us
line compani report oppenheim co inc estim
phase ii nanoflu studi evalu arm includ differ antigen level
quadrival vaccin without matrix adjuv importantli studi
activ control arm fluzon hd trival vaccin current market share leader
vaccin elderli subject base superior hai profil compar compet
product support futur develop view nanoflu need demonstr
compar higher hai titer fluzon hd least one strain
strain respons major sever infect requir hospit
last posit data either rsv nanoflu data support busi
develop interest larg pharmaceut compani includ potenti
sale compani view rsv program particularli time base
requir defin regulatori commerci plan market outsid us
potenti expand addit patient popul includ copd patient
potenti revisit elderli popul pace market expans activ like
would benefit resourc pharmaceut partner believ
nanoflu program support partner interest regulatori pathway influenza
vaccin well defin view complet phase develop may
eventtim importancetoplin phase ii data nanoflu phase data matern vaccin phase studi develop rsv bla matern vaccin rsv outperform
vaccin compani focus primarili develop new recombin
vaccin base virus-lik particl vlp technolog relat expertis
recombin nanoparticl opinion compani core expertis
construct vlp enabl use much less complex potenti lower
cost manufactur process tradit vaccin product process
opinion strong patent protect composit manufactur use
vlp vaccin caveat lawyer
compani current three in-hous vaccin program rsv phase season
influenza phase ii ebola preclin develop
nvax vlp technolog self-assembl non-infecti protein structur close
mimic natur viru compani build structur similar viru except
remov one two gene viral genom associ viral replic
follow immun vlp attach cell trigger innat adapt
immun respons may suffici protect patient futur infect
influenza vaccin immun respons thought trigger function
properti two surfac protein hemagglutinin neuraminidas
primari clinic advantag vlp influenza vaccin compar altern vaccin
product method flexibl close match specif viral strain lead
robust immun respons addit preclin model suggest
compani vlp vaccin maintain robust immun respons low dose without
patent surround composit manufactur use vlp
technolog importantli compani issu patent vlp matrix scaffold
form intern core vlp vaccin program patent use
vaccin immunolog agent patent cover process improv
clinic overview rsv market
rsv infect common caus bronchiol pneumonia among children
age one common among pediatr elderli popul cdc
estim rsv account nearli hospit death
year unit state mortal concentr infant elderli
infect rate compar industri countri infect
preval among newborn nearli children experienc rsv infect prior
second birthday
case rsv envelop rna viru present clinic relev
symptom children infect rsv develop symptom
bronchiol pneumonia upon first infect accord cdc total
rsv infect requir hospit accord cdc translat
roughli case annual unit state among children age
year major hospit children month age furthermor cdc
estim rsv infect associ million annual outpati visit children
year age
take annual rsv-associ hospit rate case among pediatr
patient like underst true incid due poor diagnost infrastructur limit
incid rsv lower among adult portion case lead
hospit may higher consult iv estim million adult unit
state western europ contract rsv infect year caus
hospit mani hospit elderli patient age
co-morbid annual rsv lead death adult older year
age us per cdc
incub period rsv day typic case resolv week
onset symptom transmiss rsv follow season pattern similar
influenza higher transmiss rate fall winter earli spring rsv spread
respiratori secret close contact infect person contact
contamin surfac object numer studi shown infant sever rsv
infect also increas rate asthma children young adult
treatment option sever rsv infect limit virazol aerosol ribavirin
bausch health compani product
approv treatment hospit infant young children sever lower
respiratori tract infect caus rsv sinc us approv virazol
limit commerci success due variabl efficaci signific safeti concern
oner treatment regimen hour per day day moreov american
academi pediatr committe infecti diseas recommend routin use
ribavirin treat rsv due lack clinic evid efficaci
current prevent option includ good infect control practic rsv-ivig
anti-rsv human murin monoclon antibodysynagi palivizumab
astrazeneca view synagi approv prevent rsv infect
neonat direct competitor either vaccin rsv therapeut
clinic develop due use synagi high-cost prophylaxi high-risk
popul absenc data support use treatment set
difficult develop histori rsv vaccin
rsv infect repres signific public health concern histori vaccin
develop indic mark signific setback may impact
regulatori attitud toward futur clinic trial view
research commonli use variou form inactiv viru vaccin develop
strategi produc protect antibodi approach tri
formalin-inactiv alum-precipit rsv fi-rsv vaccin sever infant
develop enhanc respiratori diseas subsequ infect rsv
precis mechan action enhanc respiratori diseas never
explain subsequ develop subunit vaccin demonstr
evid enhanc respiratori diseas research hypothes
reaction fi-rsv vaccin may relat contamin non-vir
protein regardless sourc enhanc respiratori diseas case studi
rais safeti hurdl develop rsv vaccin
begin research explor develop sever subunit rsv
vaccin although vaccin gener safe gener immunogen
respons antibodi appear limit function activ immun
offer littl protect rsv infect
may complet enrol phase prepar studi
enrol healthi pregnant women receiv nanoparticl antigen alum
adjuv placebo random enrol stop base achiev
patient enrol vaccin cohort phase dose disclos
expect studi incorpor rsv protein aluminum
adjuv dose use phase ii
primari endpoint infant protect symptomat rsv lower respiratori tract
infect hypoxemia first day life protocol call interim
efficaci analysi conduct month enrol last infant born
suggest januari estim may compani disclos fda
concurr interim analysi serv basi bla file
allow week complet follow-up januari analyz data
expect announc interim data late manag hope file bla
track review could support approv late earli
view timelin would allow captur econom
august present top-lin result phase ii studi rsv f-
protein vaccin healthi subject least year age subject
enrol across us site random receiv rsv protein
salin placebo base infect per protocol analysi patient
control arm natur rsv infect rate defin consist
previou public suggest annual infect rate compar
control arm vaccine-tr patient per protocol basi
reduct lower respiratori tract rsv diseas
furthermor patient sever infect benefit vaccin
product reduct patient
symptom reduct vaccin demonstr
reduct symptomat rsv infect vs reduct rsv lower-
respiratori tract infect vs importantli greatest benefit demonstr
sever infect reduct patient symptom vs
reduct patient symptom vs
kaplan-mei curv demonstr continu diverg rate rsv-associ
ill vaccin control cohort month suggest potenti
protect across entir rsv season addit immunogen consist
prior studi anti-f igg pca titer peak day plateau day
remain protect level day specif peak pca igg
concentr increas baselin serorespons occur
patient respect rsv f-protein safe well toler
elderli patient nearli ident safeti profil placebo term local
phase failur adult
septemb present top-lin result phase resolv studi
rsv f-protein vaccin adult age year older miss primari
endpoint event moderate-to-sever rsv-associ lower respiratori tract infect
among vaccin vs control similar vs rsv
 vaccin led numer reduct symptomat rsv infect vs
result signific similarli result phase iib
booster dose studi previous vaccin elderli adult fail show reduct
manag attribut disappoint data lower rsv attack rate attack rate
moderate-to-sever rsv-associ lower respiratori tract infect
symptomat rsv infect vs phase ii studi
attack rate booster studi similar phase
acknowledg lower attack rate increas difficulti demonstr vaccin
efficaci upper bound confid interv suggest increas power might
rais vaccin efficaci margin efficaci
present result phase rsv vaccin trial fifth vaccin
intern societi vaccin isv confer held octob base
poster present believ vaccin may elicit suffici antibodi titer
rsv protein target synagi provid function immun rsv
compar placebo treatment group show statist signific increas
geometr mean titer gmt day day importantli highlight
exhibit vaccin demonstr clear dose respons impact rsv
 antibodi respons administr second dose day appear
modest particularli higher dose addit alum adjuv appear increas
total anti-rsv respons immunogen respons function synagi
peptid see exhibit durat mainten protect antibodi level
evalu phase studi
seen exhibit antibodi titer rsv protein significantli higher
placebo cohort day day importantli subject
receiv vaccin record seroconvers day includ subject
highest dose vaccin combin adjuv
exhibit impress immun respons without adjuv
plaqu reduct neutral titer prnt also measur significantli
higher day vaccin group contain adjuv compar
placebo importantli increas rsv antibodi synagi
peptid view relev metric measur format
function activ antibodi like offer clinic protect rsv infect
mention addit alum adjuv appear particularli notabl
impact format antibodi synagi peptid
exhibit synagis-lik antibodi relev newborn
last advers event roughli line expect local pain
tender predomin mostli mild aberr dose-respons
inject site reaction vaccine-rel seriou advers event system
signal observ studi
base avail inform nvax rsv vaccin high safeti hurdl
creat advers event earlier rsv vaccin studi newborn
seek regulatori approv matern vaccin altern direct vaccin
babi
believ expect mother unlik comfort matern
vaccin howev base review literatur discuss ob/gyn
think signific portion market would recept matern vaccin
product strong safeti profil
financi forecast start defin portion target market current receiv
season influenza vaccin literatur influenza vaccin rate
pregnant women limit believ survey conduct acog
advisori committe immun practic offer credibl benchmark
survey found pregnant women receiv influenza vaccin rate
nearli twice high gener popul childbear age believ
survey may reflect certain level select bia wed also note expect mother
receiv much higher level support care prevent treatment non-
pregnant women compar age may explain unexpectedli high influenza
rsv vaccin rangeplaceboloc event phase rsv studi novavax inc
exhibit flu offer benchmark rsv vaccin pattern
us matern vaccin market adopt curv assum launch
total number birth expect increas us histor rate
annual result increas number live birth million
assum roughli expect mother million attend major
prenat visit ob/gyn theoret maximum market size
base data acog survey assum women receiv appropri
prenat care receiv season influenza vaccin pregnanc target market
million birth annual expect nvax vaccin achiev peak market
share target market roughli million dose price
around sale us
although compar data influenza vaccin rate expect mother
avail europ appli similar vaccin rate yield target market
million pregnanc reflect demograph trend expect birthrat europ
declin annual cours revenu model peak market penetr
estim base limit experi state health system reimburs
matern vaccin regimen assum nearli payment pocket yield
peak sale believ market matern vaccin
certain asian countri includ region revenu model due lack
reliabl data matern vaccin practic
total model call world-wide sale matern vaccin market
expect partner program collect royalti futur sale
forecast royalti rate
vaccin effect treatment rsv infect infant young children
newborn high risk rsv receiv monthli inject synagi prophylaxi
immun system fulli develop american academi pediatr
provid updat guidelin synagi prophylaxi limit scope high risk
product label despit limit use product gener net sale
prior guidelin chang
synagi palivizumab human monoclon antibodi develop medimmun
approv fda june synagi direct rsv-specif surfac
glycoprotein rsv prevent seriou respiratori diseas includ pneumonia
bronchiol caus rsv infect intend use restrict high-risk
prematur babi born week gestat age babi congenit heart
diseas product typic administ intramuscular inject given
monthli throughout rsv season novemberapril northern hemispher
infant receiv maximum dose rsv season
fda approv synagi base random double-blind placebo-
control phase studi impact-rsv high-risk pediatr patient studi
evalu synagiss efficaci prevent seriou rsv measur rsv
hospit patient random synagi studi less rsv
hospit compar patient placebo group vs
matern vaccin market modeltot birthsproject growth number receiv adequ matern popul matern rsv vaccin expect mother receiv influenza vaccin pregnanaci matern popul rsv mother vaccin rsv rsv per rsv price per sale rsv vaccin rsv vaccin matern revenu matern vaccin market modeltot eu birthsproject growth eu number eu eu receiv adequ matern popul matern rsv vaccin expect mother receiv influenza vaccin matern popul rsv mother vaccin rsv rsv per rsv price per sale rsv vaccin rsv vaccin matern revenu rsv vaccin matern royalti revenu american colleg obstetrician gynecologist advisori committe immun practic survey novavax inc
exhibit current guidelin use synagi
murray et al impact palivizumab guidelin revis incid rsv children resid long-term facil poster id
guidelin rsv provid updat recommend synagi
inject children outlin exhibit guidelin materi narrow
recommend popul dose potenti increas number non-
prophylax infant higher-than-averag rate rsv infect
id week investig present poster evalu impact revis
guidelin synagi use may young children specif data
day rsv rate greater post-guidelin chang adjust studi
site age vs per resid day ci
studi enrol children three pediatr long-term care facil greater
new york citi area mean age year patient
chronic lung diseas tracheostomi ventilator-depend
total infect occur includ children less year age
overal rsv infect rate per resid day
mention effect prophylaxi treatment rsv infect
hospit infant young children given limit synagi nebul
ribavirin limit efficaci increas risk anemia signific unmet need
new therapi treat sever rsv infect pediatr transplant patient elderli
patient high-risk popul
view rsv competit landscap bifurc prevent method
via target prophylaxi high-risk patient broad-bas vaccin would
effect reduc size address market rsv treatment small
molecul therapeut approach global biopharmaceut compani includ
johnson johnson treat rsv infect safeti profil
guidelin rsv recommend synagi categorypre- data avail sever immunocompromis infantsinf month old congenit abnom airway neuromuscular diseaseinfact children month old hemodynam signific cyanot acyanot congenit heart diseaseyesno chronic heart diseas monthsconsiderno chronic lung diseas monthsyesno weeksno insuffici data insuffici data yesconsid month age down syndromeyesyesy supplement oxygen birth day continu medic support start rsv seasonyesnopreterm infant week gestat month oldpreterm infant week gestat month oldchron lung diseas month old medic therapyinf week month rsv seasoncyst fibrosisinf breakthrough rsv infect ie continu prophylaxi ye outperform
gener adequ pediatr patient view extend
half-lif rsv antibodi medimmun sanofi strongest competitor
potent kappa anti-rsv mab deriv human cell design
target conserv epitop prefus conform rsv protein
fc portion antibodyto enhanc bind neonat
fc receptor acid condit ph lysosom therebi prevent
degrad increas recircul molecul expect support potenti
singl infus prophylaxi month protect deliv fix
intramuscular inject program develop joint collabor
medimmun sanofi
mab posit potenti single-dos passiv immun pre-term
term infant enter first rsv season children chronic lung diseas
congenit heart diseas enter first second rsv season receiv
fda track design april prevent lower respiratori tract
infect caus rsv infant young children
rel synagi achiev greater neutral activ
divers panel rsv strain higher potenc reduc lung
viral load log cotton rat model rsv similar serum
concentr term half-lif extens yte-modifi antibodi achiev
increas half-lif cynomolgu monkey versu unmodifi drug candid
id week medimmun present full result phase ib/iia first-in-inf
studi singl intramuscular dose pre-term infant
week gestat enter first rsv season elig synagi data
suggest potenti protect serum concentr valu
day post-dos base data medimmun advanc
doseth highest dose test phase ib/iia studyfor phase iib studi
healthi pre-term infant week gestat elig synagi phase iib
clinic trial expect complet decemb accord clinicaltri gov
result studi releas expect data present
medimmun expect conduct futur phase program healthi full-
term late-preterm infant
march medimmun sanofi announc agreement jointli develop
commerci prevent lower respiratori tract diseas caus rsv
infect pursuant term agreement medimmun receiv up-front
elig develop sale mileston medimmun
sanofi split cost profit medimmun lead develop activ
initi approv maintain manufactur control sanofi respons
commerci effort
on-going phase iib studi designpreterm infant week gestat
novemb medimmun dose first patient double-blind random
phase iib studi evalu singl intramuscular dose prevent
medically-attend lower respiratori tract rsv infect versu placebo studi
enrol healthi pre-term infant week gestat enter
first rsv season elig synagi local guidelin infant
exclud base fever respiratori ill within day random acut ill
random activ rsv infect prior rsv mab rsv vaccin includ
matern vaccin enrol conduct site us canada
europ southern hemispher
enrol patient random placebo via intramuscular
inject primari endpoint incid medic attend lower respiratori
infect due pcr-confirm rsv day post-dos secondari endpoint
includ hospit due pcr-confirm rsv day safeti
toler treatment-emerg advers event treatment-emerg seriou advers
event advers event special interest aesi new onset chronic diseas nocd
serum concentr incid anti-drug antibodi
safeti pk assess studi complet day
first-in-inf phase ib/iia studi pre-term infant week gestat
phase ib/iia studi enrol pre-term infant week week gestat enter
first rsv season elig synagi local guidelin
clinic trial enrol site us south africa chile total
infant enrol januari septemb infant follow
dose escal studi random patient singl fixed-dos intramuscular
placebo primari
endpoint safeti toler day post dose secondari endpoint
includ serum concentr anti-drug antibodi day exploratori
endpoint includ preliminari efficaci base pcr test nasal sampl
infant lower respiratori diseas seek medic attent anti-rsv
neutral antibodi titer serum day
murray et al impact palivizumab guidelin revis incid rsv children resid long-term facil poster id
baselin demograph similar across treatment group exhibit except
cohort slightli younger lighter infant random
complet protocol-defin end studi patient lost follow-up
day reloc
indian alaskan kg day age outperform
domachowsk et al singl dose monoclon antibodi immunoprophylaxi strategi prevent rsv diseas infant result first
infant studi abstract id week
serum concentr assess day month month month
post-dos day target serum concentr rsv level
observ infant dose data suggest elev
serum concentr suffici potenti protect month
rsv neutral antibodi titer cohort least rise serum titer
baselin day
base serum concentr profil singl intramuscular inject
select dose phase iib develop
preliminari clinic efficaci outcom total event bronchiol
lower respiratori tract infect includ event cohort
placebo addit infant met criteria
medic attend lower respiratori tract infect includ infant
dose respect
total six infant nasal sampl collect pcr test total two sampl
rsv posit third hmpv posit patient cohort
medic attend lower respiratori tract infect rsv posit infant also
posit hmpv differ time point addit infant arm
meet criteria medic attend lower respiratori tract infect rsv posit
ill onset day post dose two infant pcr-posit rsv twin
take may reduc rate rsv infect pre-term birthsand
potenti pediatr casesbut effect newborn limit product
primari market pediatr patient year age
across cohort infant develop anti-drug antibodi
dose total patient transient anti-drug antibodi detect day
post dose infant detect anti-drug antibodi day
patient anti-drug antibodi detect antibodi
target modifi yte domain fc region anti-drug antibodi impact
safeti pk day day pk may impact
subject view
respect safeti nearli patient experienc advers event total
event cohort determin treatment-rel total seriou
event occur activ cohort result hospit common advers
event line common diagnosi infant first month life
exhibit treatment-rel
domachowsk et al singl dose monoclon antibodi immunoprophylaxi strategi prevent rsv diseas infant result first
infant studi abstract id week
season flu offer second attract growth
annual season influenza market rel matur shift toward
higher price quadrival vaccin steadi age popul north america
europ translat steadi high single-digit growth revenu basi past
year glaxosmithklin novarti sanofi domin market intramuscular
vaccin manufactur chicken egg astrazeneca medimmun divis
septemb initi phase ii studi nanoflu studi includ
dose cohort five differ formul nanoflu trival fluzon hd
undisclos commerci quadrival vaccin first four dose cohort receiv
formul nanoflu day zero placebo day clinicaltri gov
disclos nanoflu dose use cohort view like
explor two level antigen without compani matrix-m adjuv
final three cohort evalu combin includ approv vaccin
benchmark efficaci nanoflu patient fifth cohort receiv nanoflu
day zero follow commerci avail flu vaccin day cohort
six benchmark fluzone-hd market share leader elderli popul
singl inject day zero placebo day final cohort provid
baselin immunogen singl inject commerci avail quadrival
grade saeae lead hospit lower respiratori tract infect day hmpv hospit febril convuls day hospit febril convuls day concurr lower respiratori tract infect day outperform
made two present describ data phase i/ii
studi nanoflu recombin influenza vaccin present demonstr
higher hai respons homolog strain a/ hong kong higher
forward-drift strain a/singapor higher histor strain a/switzerland
three comparison fluzon hd trival vaccin gener regard
potent fda approv vaccin
present world vaccin congress entitl novavax nanoflu vaccin
demonstr consist improv hai geometr mean fold titer rise across
numer strain higher dose a/victoria a/texa
a/switzerland a/hong kong a/singapor
result numer greater strain fluzone-hd cohort low-
dose nanoflu demonstr hai geometr mean fold titer rise almost exactli ident
fluzon hd strain
patient enrol three site north carolina patient age
year dose cohort stratifi age age subject
receiv singl intramuscular inject dose fluzon hd label dose
nanoflu matrix-m adjuv nanoflu matrix-m
adjuv trival vaccin design protect a/michigan
a/hong kong b/brisban strain
primari endpoint hai antibodi titer day safeti also evalu
tniv ha tniv ha fluzon age american hispan vaccin flu vaccin w/i yr novavax inc
preclin data suggest superior fluzon hd
august paper publish vaccin evalu nanoflu
commerci avail trival fluzon hd fluzon quadrival ferret model
takeaway paper includ hai titer higher
fold higher strain compar fluzon hd microneutr
strain circul suggest potenti
cross-protect higher hai titer victoria strain compar fluzon
hd remind two primari strainsvictoria yamagatahav
demonstr cross-react prior studi
specif total cohort serolog neg subject inocul
inject week apart day week dose subject challeng
one differ strain viru nasal wash collect everi day day
hai titer collect day higher higher
strain compar fluzon hd hai titer victoria strain
higher microneutr titer gener correl hai titer nasal wash viral titer
lower nanoflu subject time point reach lower limit
quantif day compar day fluzon hd viral titer data combin
hai find suggest potenti superior protect nanoflu particularli
elderli popul fluzon hd
market revenu model season influenza market assum us suppli
increas annual next year reach million dose
believ increas suppli egg-bas manufactur new entrant
like place cap price current averag per dose
expect compani win fda approv season
influenza vaccin assum price line product per dose
price increas time expect captur us
market million dose translat peak us sale
assum compani sell product directli group purchas
organ larg distributor nomin sell expens recogn gross
margin
europ expect vaccin suppli grow annual total million dose
model call sell distributor captur roughli
market sale roughli model call record
royalti
safeti event thru tniv ha tniv ha fluzon treatment emerg advers event solicit local system relat advers event count subject event outperform
believ vaccin enjoy signific barrier entri potenti competitor
relat manufactur know-how requir extens safeti character
intellectu properti provid import secondari barrier entri
approxim us correspond foreign patent pend applic relat
vlp platform
term protect rsv nanoparticl program key us patent seri
method use patent modifi rsv vaccin patent
patent protect compani propreitari matrix
adjuv patent forc
juli announc sign nonexclus world-wide licens
agreement wyeth relat patent applic cover vlp technolog use
human influenza vaccin agreement provid up-ront payment annual
licens fee mileston payment undisclos royalti estim
relat patent expir expect make materi futur
payment agreement
market modeldos purchas accord cdc project growth season influenza season influenza share season influenza season influenza per season influenza price per sale season influenza vaccin season influenza vaccin revenu market modeldos purchas accord iv project growth season influenza eu season influenza share season influenza season influenza per season influenza price per sale season influenza vaccin season influenza vaccin revenu pacif primarili japan australia market modeldos purchas accord iv project growth season influenza western pacif season influenza share season influenza season influenza per season influenza price per pacif sale season influenza vaccin pacif season influenza vaccin revenu season influenza vaccin royalti revenu inc
model call begin recogn posit cash flow oper late
compani nol tax asset decemb
expect tax asset combin addit oper loss next year
protect earn feder tax least expect compani
record tax rate subsequ period
expect gener materi commerci product revenu fda
approv compani rsv vaccin matern vaccin prevent infect
newborn expect late view eps-driven stori
time encourag investor focu clinic develop regulatori
mileston primari avenu creation sharehold valu
expect cash burn rate peak complet phase
rsv studi remain elev given substanti fix cost associ
manitain commercial-scal manufactur infrastructur potenti cost
conduct pivot studi nanoflu estim burn
balanc septemb fund
oper view
sale expect recogn reimburs melinda gate
foundat portion phase develop rsv program grant revenu
expect revenu total expect
record signific product revenu us rsv launch late earli
cog global commerci scale expect rsv vaccin record gross margin
around given abund global capac influenza vaccin product
view unlik build commerci scale product like share
expens either commerci partner government organzi
 forecast call administr expens rise modestli posit
phase rsv studi expans preliminari pre-commerci activ net
expect report expens
respecitv long term expect cost increas annual
 forecast spend
respect assum modest amount pre-launch inventori build rsv
program believ work capit expens flow
regulatori approv could substanti predict time uncertain
ep expect record earn per share
respect smaller loss per share associ part higher
share count follow compani equiti financ april share issu
at-the-market stock issuanc program expect compani
achiev profit current cash balanc may fund oper
addit access cash partern one program issuanc debt
issuanc addit equiti necessari fund oper profit
integr vaccin develop compani personnel manufactur
vaccin product develop march full-tim
employe includ roughli employe alloc manufactur
believ compani necessari leadership staf support bla
file rsv flu program next month next leadership
inflect point come potenti global commerci rsv vaccin
view base case assum partner product sell compani
respons build global field sale forc manag previous
acknowledg global vaccin industri matur busi mark high
level supplier concentr interpet comment evid manag
would support sale larger competitor appropri price
chief execut offic stanley erck join compani board director june
name execut chairman februari presid chief execut
offic director april prior join compani serv chief
execut vaccin deliveri compani iomai corp acquisit
intercel earlier career mr erck held leadership posit procept inc
integr genet serv board director
maxcyt inc mdbio foundat
presid research develop prior join juli gregori glenn
work directli ceo erck iomai corp respons overse
develop iomai vaccin patch technolog associ editor
journal expert review vaccin human vaccin dr glenn receiv degre
biolog chemistri whitman colleg doctor medicin oral robert
univers school medicin medic research fellowship walter reed
armi institut research
svp chief medic offic loui fri vice presid clinic regulatori
affair influenza vaccin start-up id biomed corp compani acquir
glaxosmithklin subsequ serv director clinic develop
glaxosmithklin join hold primari oversight
compani influenza vaccin program dr fri train nation institut
allergi infecti diseas member laboratori clinic
investig receiv degre john hopkin univers
duke univers author peer-review public
svp busi offic chief offic john trizzino overse
compani commerci strategi market develop activ rsv vaccin
program also serv cfo rejoin compani serv svp
commerci oper ad cfo respons mr trizzino
commerci expertis develop primarili tenur medimmun id
biomed also ceo canadian immuno-oncolog start-up
immunovaccin receiv bs long island univers cw
new york univers
svp global manufactur oper timothi hahn join senior vice
presid manufactur june respons overse scale-up
compani clinical-stag vaccin program prior respons
us non-u manufactur facil medimmun also work vaccin
manufactur merck co year dr hahn receiv doctor
master scienc degre chemic engin stanford univers
risk clinic trial failur phase rsv program failur nanoflu
demonstr differenti efficaci profil commerci avail flu vaccin
disrupt manufactur suppli chain includ scale-up rsv nanoflu
program commerci scale reimburs first-in-class potenti best-
in-class vaccin offer premium price
compani document oppenheim co inc estim
product research profit incom profit continu averag common gain incom loss loss per share novavax inc
compani document oppenheim co inc estim
short term account current properti intang account accru compens defer current portion current convert equiti paid-in comprehens treasuri retain earn sharehold outperform
stock price compani mention report
